Data Raise Hopes Of Accelerated Approval For Hansa's Kidney Transplant-Enabling Imlifidase

Kidney transplantation might be possible in difficult-to-graft highly sensitized patients using Hansa Medical's IgG-cleaving product, imlifidase. The high unmet need for such a product might usher in a Phase II data-based approval.  

Kidney

The potential of Hansa Medical AB's lead product, imlifidase, to enable kidney transplantation in highly sensitized patients, as shown in positive final top-line results from two Phase II clinical studies in 35 patients, has led the company to start planning for possible approval filings in the next several quarters, and the building of commercialization infrastructure in the US and elsewhere.

Hansa Medical is seeking end-of-Phase II meetings with regulators in the EU and US with a view to pursuing accelerated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Genitourinary

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By 

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Still Looking For A Gene Therapy Hit, Syncona Backs Purespring In IgA Nephropathy Market

 

Purespring has just raised $105m from an investor syndicate who are betting it can develop the first gene therapy for kidney disease and learn from setbacks experienced in the space.

REGENCY Dandy for Roche In Lupus Nephritis

 

Gazyva could add the autoimmune condition to its label following a Phase III hit, but it might struggle to differentiate itself from Benlysta and Lupkynis.    

AstraZeneca Believes Size Matters In Amyloidosis

 

Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.    

More from Therapy Areas

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.